Monday, May 4, 2015

Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial



Evacetrapib.svg
We know that, Evacetrapib  is a  drug under  development by  Eli Lilly  and  company (investigational   name   LY2484595)      that inhibits cholesterylester transfer protein (CETP), which  transfers and thereby increases high-density lipoprotein and     lowers   low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the    risk     of     cardiovascular   disease.   The  first  CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied.  Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.


A recent report states that,  Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. The decision is not based on any data from ACCELERATE, as both the academic committee and the company remain blinded to efficacy results............

No comments: